Genomics, internationally recognized speakers to figure prominently in upcoming symposium

March 27, 2002

A special symposium, Exploring Medicine in the Post-Genome World, will take place April 19-20 during the University of North Carolina at Chapel Hill School of Medicine's Spring Medical Alumni-Medical Center 50th Anniversary celebrations.

The symposium will be held at the William and Ida Friday Continuing Education Center and in Berryhill Hall on the UNC campus. During the 2-day event, nationally and internationally recognized speakers will address a variety of subjects: Among them: "Genome Variation and the Genetic Features of Complex Human Diseases;" "Genomics: Changing America's Healthcare System;" "Human Evolution and its Meaning for Medical Genetics;" "Functional Genomics in Drug Discovery;" "Fetal Determinants of Adult Health" and "The Accumulation and Expression of Natural Genetic Variation."

"The genome projects are having a profound impact on health care delivery. The purpose of the symposium is to articulate some of the expected changes as we look ahead to the next 50 years of medicine at UNC-Chapel Hill," said Terry Magnuson, Ph.D., Kenan professor of genetics and director of the Carolina Center for Genome Sciences.

Among the distinguished speakers are Drs. Lee Hartwell and Francis Collins. Hartwell, director of Fred Hutchinson Cancer Research Center in Seattle, won the 2001 Nobel Prize in Physiology or Medicine for his discoveries on regulation of the cell cycle. His findings expanded the understanding of how normal cells divide and the mechanisms behind the uncontrolled growth of cancer cells. Collins, a physician-geneticist and 1977 graduate of UNC-Chapel Hill School of Medicine, directs the National Human Genome Research Institute at NIH.

Symposium registration is required, deadline April 12. Individuals planning to attend can find program and registration information at: or contact the Office of Continuing Medical Education, 919-843-6382.
media note: Contact Magnuson at 919-843-6475,
School of Medicine contact, Les Lang, 919-843-9687,

University of North Carolina Health Care

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to